Immutep

Phase I

image Immutep S.A. announced today that it has initiated a Phase I clinical trial of its lead product ImmuFact® IMP321 in metastatic renal cell carcinoma. This is the Company's first clinical trial targeting cancer. Immutep is already carrying out trials of IMP321 to show safety and immune response to infectious disease antigens in healthy volunteers. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response through activation of dendritic cells and more efficient antigen presentation to T cells.

Please, click on ADOBE PDF logo to read the complete communique.

Published 11/2005 by admin@immutep.com
» Office and Laboratory Leases
© 2002 Immutep, S.A.
Press Release
10/2008 - IMP321 IND Allowance in Pancreatic Cancer
image Immutep S.A. announced today that the FDA, after review of the ...
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy
image Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer
image Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients
image Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I
image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...